Acute effect of high-intensity interval aerobic exercise on serum myokine levels and resulting tumour-suppressive effect in trained patients with advanced prostate cancer.


Journal

Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 21 09 2022
accepted: 17 11 2022
revised: 15 11 2022
medline: 13 11 2023
pubmed: 30 11 2022
entrez: 29 11 2022
Statut: ppublish

Résumé

Although skeletal muscle releases cytokines called myokines during exercise, the kinetics of the acute myokine response to exercise (exercise-induced circulatory myokine level alteration) is unknown in patients with advanced prostate cancer. We measured myokine levels in serum obtained from patients with metastatic castrate-resistant prostate cancer (mCRPC) before and after exercise and assessed the growth-suppressive effect of the serum by applying it to a PCa cell line. Nine patients with mCRPC (age = 67.8 ± 10.1 years, time since mCRPC diagnosis 36.2 ± 22.5 months) undertook 34 min of a high-intensity interval exercise session on a cycle ergometer. Blood was collected immediately pre, post and 30 min post. Serum levels of secreted protein acidic and rich in cysteine (SPARC), oncostatin M (OSM), interleukin-6 (IL-6), interleukin-15 (IL-15), decorin, irisin, and IGF-1 were determined. Growth of the androgen-independent PCa cell line DU-145 exposed to serum collected at three points was measured. There was a significant elevation of SPARC (19.9%, P = 0.048), OSM (11.5%, P = 0.001), IL-6 (10.2%, P = 0.02) and IL-15 (7.8%, P = 0.023) in serum collected immediately after exercise compared to baseline, returning to baseline after 30 min rest. A significant reduction in DU-145 Cell growth and the Cell Index area under the curve at 72 h incubation was observed with the presence of serum obtained immediately post-exercise (Cell Index at 72 h: 16.9%, P < 0.001; area under the curve: 15.2%, P < 0.001) and with the presence of serum obtained 30 min post-exercise compared to baseline (Cell Index at 72 h: 6.5%; area under the curve: 8.8%, P < 0.001). This study provides preliminary evidence for an acute exercise-induced myokine response and tumour growth suppression in serum after a bout of high-intensity interval exercise in patients with advanced PCa.

Identifiants

pubmed: 36446945
doi: 10.1038/s41391-022-00624-4
pii: 10.1038/s41391-022-00624-4
doi:

Substances chimiques

Interleukin-6 0
Interleukin-15 0
Osteonectin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

795-801

Subventions

Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : APP1116334

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Schmitz KH, Campbell AM, Stuiver MM, Pinto BM, Schwartz AL, Morris GS, et al. Exercise is medicine in oncology: Engaging clinicians to help patients move through cancer. CA Cancer J Clin. 2019;69:468–84.
doi: 10.3322/caac.21579 pubmed: 31617590 pmcid: 7896280
Galvao DA, Taaffe DR, Spry N, Cormie P, Joseph D, Chambers SK, et al. Exercise preserves physical function in prostate cancer patients with bone metastases. Med Sci Sports Exerc. 2018;50:393–9.
doi: 10.1249/MSS.0000000000001454 pubmed: 29036016
Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: A randomized controlled trial. J Clin Oncol. 2010;28:340–7.
doi: 10.1200/JCO.2009.23.2488 pubmed: 19949016
Lopez P, Taaffe DR, Newton RU, Galvao DA. Resistance exercise dosage in men with prostate cancer: Systematic review, meta-analysis, and meta-regression. Med Sci Sports Exerc. 2020;53:459–69.
doi: 10.1249/MSS.0000000000002503 pmcid: 7886340
Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011;29:726–32.
doi: 10.1200/JCO.2010.31.5226 pubmed: 21205749 pmcid: 3056656
Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res. 2011;71:3889–95.
doi: 10.1158/0008-5472.CAN-10-3932 pubmed: 21610110 pmcid: 3107352
Dethlefsen C, Hansen LS, Lillelund C, Andersen C, Gehl J, Christensen JF, et al. Exercise-induced catecholamines activate the hippo tumor suppressor pathway to reduce risks of breast cancer development. Cancer Res. 2017;77:4894–904.
doi: 10.1158/0008-5472.CAN-16-3125 pubmed: 28887324
Dethlefsen C, Lillelund C, Midtgaard J, Andersen C, Pedersen BK, Christensen JF, et al. Exercise regulates breast cancer cell viability: systemic training adaptations versus acute exercise responses. Breast Cancer Res Treat. 2016;159:469–479.
doi: 10.1007/s10549-016-3970-1 pubmed: 27601139
Devin JL, Hill MM, Mourtzakis M, Quadrilatero J, Jenkins DG, Skinner TL. Acute high intensity interval exercise reduces colon cancer cell growth. J Physiol. 2019;597:2177–84.
doi: 10.1113/JP277648 pubmed: 30812059 pmcid: 6462486
Hwang JH, McGovern J, Minett GM, Della Gatta PA, Roberts L, Harris JM, et al. Mobilizing serum factors and immune cells through exercise to counteract age-related changes in cancer risk. Exerc Immunol Rev. 2020;26:80–99.
pubmed: 32139350
Rundqvist H, Augsten M, Stromberg A, Rullman E, Mijwel S, Kharaziha P, et al. Effect of acute exercise on prostate cancer cell growth. PLoS ONE. 2013;8:e67579.
doi: 10.1371/journal.pone.0067579 pubmed: 23861774 pmcid: 3702495
Fiuza-Luces C, Garatachea N, Berger NA, Lucia A. Exercise is the real polypill. Physiol (Bethesda). 2013;28:330–58.
Pedersen BK. The Physiology of optimizing health with a focus on exercise as medicine. Annu Rev Physiol. 2019;81:607–27.
doi: 10.1146/annurev-physiol-020518-114339 pubmed: 30526319
Kim J-S, Galvão DA, Newton RU, Gray E, Taaffe DR. Exercise-induced myokines and their effect on prostate cancer. Nat Rev Urol. 2021;18:519–42.
doi: 10.1038/s41585-021-00476-y pubmed: 34158658
Shin M, Mizokami A, Kim J, Ofude M, Konaka H, Kadono Y, et al. Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin β1. Prostate. 2013;73:1159–70.
doi: 10.1002/pros.22664 pubmed: 23532895
Tekin S, Erden Y, Sandal S, Yilmaz B. Is irisin an anticarcinogenic peptide? Med-Sci. 2015;4:2172–80.
doi: 10.5455/medscience.2014.03.8210
Hu Y, Sun H, Owens RT, Wu J, Chen YQ, Berquin IM, et al. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia. 2009;11:1042–53.
doi: 10.1593/neo.09760 pubmed: 19794963 pmcid: 2745670
Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: Defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw. 2010;8:211–23.
doi: 10.6004/jnccn.2010.0014 pubmed: 20141678 pmcid: 2900630
Reisz-Porszasz S, Bhasin S, Artaza JN, Shen R, Sinha-Hikim I, Hogue A, et al. Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol Endocrinol Metab. 2003;285:E876–888.
doi: 10.1152/ajpendo.00107.2003 pubmed: 12824080
Singh R, Bhasin S, Braga M, Artaza JN, Pervin S, Taylor WE, et al. Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/ beta-catenin and follistatin/transforming growth factor-beta signaling pathways. Endocrinology. 2009;150:1259–68.
doi: 10.1210/en.2008-0858 pubmed: 18948405
Kim JS, Taaffe DR, Galvão DA, Hart NH, Gray E, Ryan CJ, et al. Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth. Prostate Cancer Prostatic Dis. 2022;25:86–92.
doi: 10.1038/s41391-022-00504-x pubmed: 35152272 pmcid: 8853098
Kim JS, Wilson RL, Taaffe DR, Galvao DA, Gray E, Newton RU. Myokine expression and tumor-suppressive effect of serum following 12 weeks of exercise in prostate cancer patients on ADT. Med Sci Sports Exerc. 2021;54:197–205.
doi: 10.1249/MSS.0000000000002783 pmcid: 8754092
Newton RU, Kenfield SA, Hart NH, Chan JM, Courneya KS, Catto J, et al. Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL-GAP4): A multicentre, randomised, controlled phase III study protocol. BMJ Open. 2018;8:e022899.
doi: 10.1136/bmjopen-2018-022899 pubmed: 29764892 pmcid: 5961562
Febbraio MA, Ott P, Nielsen HB, Steensberg A, Keller C, Krustrup P, et al. Hepatosplanchnic clearance of interleukin-6 in humans during exercise. Am J Physiol Endocrinol Metab. 2003;285:E397–402.
doi: 10.1152/ajpendo.00134.2003 pubmed: 12857677
Hiscock N, Chan MH, Bisucci T, Darby IA, Febbraio MA. Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J. 2004;18:992–4.
doi: 10.1096/fj.03-1259fje pubmed: 15059966
Keller C, Steensberg A, Pilegaard H, Osada T, Saltin B, Pedersen BK, et al. Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J. 2001;15:2748–50.
doi: 10.1096/fj.01-0507fje pubmed: 11687509
Hojman P, Dethlefsen C, Brandt C, Hansen J, Pedersen L, Pedersen BK. Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth. Am J Physiol Endocrinol Metab. 2011;301:E504–510.
doi: 10.1152/ajpendo.00520.2010 pubmed: 21653222
Aoi W, Naito Y, Takagi T, Tanimura Y, Takanami Y, Kawai Y, et al. A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise. Gut. 2013;62:882–9.
doi: 10.1136/gutjnl-2011-300776 pubmed: 22851666
Nielsen AR, Mounier R, Plomgaard P, Mortensen OH, Penkowa M, Speerschneider T, et al. Expression of interleukin-15 in human skeletal muscle effect of exercise and muscle fibre type composition. J Physiol. 2007;584:305–12.
doi: 10.1113/jphysiol.2007.139618 pubmed: 17690139 pmcid: 2277063
Perez-Lopez A, McKendry J, Martin-Rincon M, Morales-Alamo D, Perez-Kohler B, Valades D, et al. Skeletal muscle IL-15/IL-15Ralpha and myofibrillar protein synthesis after resistance exercise. Scand J Med Sci Sports. 2019;28:116–25.
doi: 10.1111/sms.12901
Pierce JR, Maples JM, Hickner RC. IL-15 concentrations in skeletal muscle and subcutaneous adipose tissue in lean and obese humans: local effects of IL-15 on adipose tissue lipolysis. Am J Physiol Endocrinol Metab. 2015;308:E1131–1139.
doi: 10.1152/ajpendo.00575.2014 pubmed: 25921578 pmcid: 4469810
Heinemeier KM, Bjerrum SS, Schjerling P, Kjaer M. Expression of extracellular matrix components and related growth factors in human tendon and muscle after acute exercise. Scand J Med Sci Sports. 2013;23:e150–161.
doi: 10.1111/j.1600-0838.2011.01414.x pubmed: 22107086
Kanzleiter T, Rath M, Gorgens SW, Jensen J, Tangen DS, Kolnes AJ, et al. The myokine decorin is regulated by contraction and involved in muscle hypertrophy. Biochem Biophys Res Commun. 2014;450:1089–94.
doi: 10.1016/j.bbrc.2014.06.123 pubmed: 24996176
Loffler D, Muller U, Scheuermann K, Friebe D, Gesing J, Bielitz J, et al. Serum irisin levels are regulated by acute strenuous exercise. J Clin Endocrinol Metabo. 2015;100:1289–99.
doi: 10.1210/jc.2014-2932
Tsuchiya Y, Ando D, Takamatsu K, Goto K. Resistance exercise induces a greater irisin response than endurance exercise. Metabolism. 2015;64:1042–50.
doi: 10.1016/j.metabol.2015.05.010 pubmed: 26081427
Morgan AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, et al. Androgen receptor inhibitor treatment: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. Urol Oncol. 2021;39:52–62.
doi: 10.1016/j.urolonc.2020.08.003

Auteurs

Jin-Soo Kim (JS)

Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia.
School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.

Dennis R Taaffe (DR)

Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia.
School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.

Daniel A Galvão (DA)

Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia.
School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.

Timothy D Clay (TD)

Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia.
School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Department of Oncology, St John of God Subiaco Hospital, Perth, WA, Australia.

Andrew D Redfern (AD)

Department of Medical Oncology, Fiona Stanley Hospital, Murdoch, WA, Australia.
School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia.

Nicolas H Hart (NH)

Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia.
School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
School of Sport, Exercise, and Rehabilitation, University of Technology Sydney, Moore Park, NSW, Australia.

Elin S Gray (ES)

School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Centre of Precision Health, Edith Cowan University, Joondalup, WA, Australia.

Charles J Ryan (CJ)

Medical School, University of Minnesota, Minneapolis, MN, USA.

Stacey A Kenfield (SA)

Departments of Urology and Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA.

Fred Saad (F)

Department of Urology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.

Robert U Newton (RU)

Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia. r.newton@ecu.edu.au.
School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia. r.newton@ecu.edu.au.
School of Human Movement and Nutrition Sciences, University of Queensland, St Lucia, QLD, Australia. r.newton@ecu.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH